- Ensysce Biosciences press release (NASDAQ:ENSC): Net loss attributable for the fourth quarter of 2023 was $3.5 million compared to $5.5 million for the fourth quarter of 2022.
- R&D expenses were $2.2 million for the fourth quarter of 2023 compared to $6.4 million for the same period in 2022.
- Cash and cash equivalents were $1.1 million as of December 31, 2023, as compared to $1.5 million as of September 30, 2023.
Ensysce Biosciences reports Q4 results
Recommended For You
About ENSC Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| ENSC | - | - |
| Ensysce Biosciences, Inc. | ||